Literature DB >> 29311379

A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.

Olivera J Finn1.   

Abstract

The field of tumor immunology has grown around the idea that one of the important roles of the immune system is to eliminate cancer. This idea was difficult to reconcile with the accepted notion that the immune system evolved to distinguish self from nonself and therefore tumors derived from self-tissues would not be recognized. Lack of appropriate animal models prevented experimental testing of cancer immunosurveillance. This changed with the realization that the immune system evolved to recognize danger and with the advent of mouse models deficient in one or more immune function, which showed predicted increases in susceptibility to cancer. Simultaneously, technical advances that enabled the study of the human immune system provided data for the existence of tumor-specific T cells and Abs and led to molecular identification of tumor Ags, fully validating the cancer immunosurveillance hypothesis. Immunotherapy designed to strengthen cancer immunosurveillance has achieved unprecedented clinical successes.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29311379      PMCID: PMC5763509          DOI: 10.4049/jimmunol.1701302

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  93 in total

1.  Immunosurveillance as a regulator of tissue homeostasis.

Authors:  Laura Senovilla; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer
Journal:  Trends Immunol       Date:  2013-07-26       Impact factor: 16.687

Review 2.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Localization of gene for human p53 tumour antigen to band 17p13.

Authors:  M Isobe; B S Emanuel; D Givol; M Oren; C M Croce
Journal:  Nature       Date:  1986 Mar 6-12       Impact factor: 49.962

4.  Absence of thymus in a mouse mutant.

Authors:  E M Pantelouris
Journal:  Nature       Date:  1968-01-27       Impact factor: 49.962

5.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

Review 6.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 7.  Microbiota: a key orchestrator of cancer therapy.

Authors:  Soumen Roy; Giorgio Trinchieri
Journal:  Nat Rev Cancer       Date:  2017-03-17       Impact factor: 60.716

8.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

9.  Spectrum of cancer risk among US solid organ transplant recipients.

Authors:  Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin
Journal:  JAMA       Date:  2011-11-02       Impact factor: 157.335

10.  Decreased tumor surveillance in perforin-deficient mice.

Authors:  M E van den Broek; D Kägi; F Ossendorp; R Toes; S Vamvakas; W K Lutz; C J Melief; R M Zinkernagel; H Hengartner
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more
  44 in total

Review 1.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

Review 2.  The immune system utilizes two distinct effector mechanisms of T cells depending on two different life cycle stages of a single pathogen, Toxoplasma gondii, to control its cerebral infection.

Authors:  Yasuhiro Suzuki
Journal:  Parasitol Int       Date:  2019-11-25       Impact factor: 2.230

Review 3.  Mechanisms of tumor immunotherapy, with a focus on thoracic cancers.

Authors:  Simona Ferro; Veronica Huber; Licia Rivoltini
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 4.  Harder, better, faster, stronger: biochemistry and biophysics in the immunosurveillance concert.

Authors:  Maria Tello-Lafoz; Miguel M de Jesus; Morgan Huse
Journal:  Trends Immunol       Date:  2021-12-29       Impact factor: 16.687

5.  Mechanoregulation of Metastasis beyond the Matrix.

Authors:  Ekrem Emrah Er; Maria Tello-Lafoz; Morgan Huse
Journal:  Cancer Res       Date:  2022-10-04       Impact factor: 13.312

6.  Penetration of CD8+ Cytotoxic T Cells into Large Target, Tissue Cysts of Toxoplasma gondii, Leads to Its Elimination.

Authors:  Ashish Tiwari; Rancie Hannah; Jenny Lutshumba; Eri Ochiai; Louis M Weiss; Yasuhiro Suzuki
Journal:  Am J Pathol       Date:  2019-07-10       Impact factor: 4.307

7.  Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer.

Authors:  Maria Tello-Lafoz; Katja Srpan; Elisa E Sanchez; Jing Hu; Jan Remsik; Yevgeniy Romin; Annalisa Calò; Douglas Hoen; Umeshkumar Bhanot; Luc Morris; Adrienne Boire; Katharine C Hsu; Joan Massagué; Morgan Huse; Ekrem Emrah Er
Journal:  Immunity       Date:  2021-03-22       Impact factor: 31.745

8.  Activated B lymphocytes and tumor cell lysate as an effective cellular cancer vaccine.

Authors:  Kyp L Oxley; Brett M Hanson; Ashley N Zani; Gail A Bishop
Journal:  Cancer Immunol Immunother       Date:  2021-03-25       Impact factor: 6.630

9.  Vitamin E succinate exerts anti-tumour effects on human cervical cancer cells via the CD47-SIRPɑ pathway both in vivo and in vitro.

Authors:  Xiaoli Huang; Markus Neckenig; Jintang Sun; Di Jia; Yu Dou; Dan Ai; Zhaodi Nan; Xun Qu
Journal:  J Cancer       Date:  2021-05-05       Impact factor: 4.207

Review 10.  Antitumor Immunity Is Controlled by Tetraspanin Proteins.

Authors:  Fleur Schaper; Annemiek B van Spriel
Journal:  Front Immunol       Date:  2018-05-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.